Showing 911-920 of 1635 results for "".
- Nanoscope Plans Phase 3 Trial of MCO-010 to Treat Stargardt Macular Degenerationhttps://modernod.com/news/nanoscope-plans-phase-3-trial-of-mco-010-to-treat-stargardt-macular-degeneration/2482440/Nanoscope Therapeutics announced the completion of an End-of-phase 2 (EOP2) meeting with the FDA for its clinical program evaluating MCO-010 for the treatment of severe vision loss caused by Stargardt macular degeneration (SMD), supporting advancement of MCO-010 to a phase 3 registrational trial.
- Latinos En Optometry Launches Redesigned Website and New Domain Namehttps://modernod.com/news/latinos-en-optometry-launches-redesigned-website-and-new-domain-name/2482291/Latinos en Optometry, a non-profit association dedicated to gaining a broader representation of Latinos and Spanish-speaking professionals within the optometry and larger eye care professional community, announced the launch of its redesigned website and new domain name,
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo
- Study Compares Nanodropper Adaptor Versus Conventional Eye Drops for Glaucomahttps://modernod.com/news/study-compares-nanodropper-adaptor-versus-conventional-eye-drops-for-glaucoma/2482176/Nanodropper announced the publication of a company-sponsored study<
- Amring Pharmaceuticals Changes Name to Nordic Pharma Under New Ownerhttps://modernod.com/news/amring-pharmaceuticals-changes-name-to-nordic-pharma-under-new-owner/2482141/Amring Pharmaceuticals has changed its name to Nordic Pharma, effective today, following the change in ownership of the company from Sever Life Sciences to Nordic Group, a subsidiary of Sever Life Sciences, which occurred on June 1, 2023. The change in the corporate name
- Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officerhttps://modernod.com/news/ace-vision-group-names-val-kolesnitchenko-md-as-chief-scientific-officer/2482095/Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer. Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global
- Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosahttps://modernod.com/news/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa/2482078/Nanoscope Therapeutics provided an update following recent regulatory discussions with the FDA and from the scientific advice meeting with the Icelandic Medicines Agency (IMA), regarding the regulatory path of MCO-010 for the treatment of retinitis pigmentosa (RP). In connection wi
- Amring Pharmaceuticals Names Jai G. Parekh, MD, Chief Commercial Officer, Eye Care, UShttps://modernod.com/news/amring-pharmaceuticals-names-jai-g-parekh-md-chief-commercial-officer-eye-care-us/2482059/Amring Pharmaceuticals, a subsidiary of Nordic Group BV, has named Jai G. Parekh, MD, MBA, as Chief Commercial Officer, Eye Care, US. Nordic Pharma recently expanded its pharmaceutical presence in the US by acquiring Visant Medical, maker of the FDA-c
- Visiox Pharmaceuticals to be Listed on Nasdaq Through Combination with PowerUp Acquisitionhttps://modernod.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/Visiox Pharmaceuticals and PowerUp Acquisition Corp. announced the execution of a definitive agreement for a business combination that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market. The business combination is expected to close in the first quarter of